Stock PMED PEPTONIC MEDICAL AB
Add to a list
To use this feature you must be a member
Log inSign up

PEPTONIC medical AB Stock

Equities

PMED

SE0005962206

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 18:00:00 2024-01-30 EST 		5-day change 1st Jan Change
0.06 SEK -.--% Intraday chart for PEPTONIC medical AB -.--% +3.45%
05-31 Peptonic Medical Secures European Patent for Treatment of Vulvodynia MT
05-31 Peptonic Medical AB Grants Patent in Europe for Relief of Provoked Vulvodynia in Women, Product Ready for Launch CI

Financials

Sales 2022 43.63M 4.15M 5.69M Sales 2023 37.12M 3.53M 4.84M Capitalization 89.02M 8.48M 11.61M
Net income 2022 -36M -3.43M -4.7M Net income 2023 -42M -4M -5.48M EV / Sales 2022 1.14 x
Net Debt 2022 15.77M 1.5M 2.06M Net cash position 2023 6.27M 597K 817K EV / Sales 2023 2.23 x
P/E ratio 2022
-0.92 x
P/E ratio 2023
-2.09 x
Employees 28
Yield 2022 *
-
Yield 2023
-
Free-Float 1.49%
More Fundamentals * Assessed data

Chart PEPTONIC medical AB

Dynamic Chart

Latest news about PEPTONIC medical AB

Peptonic Medical Secures European Patent for Treatment of Vulvodynia MT
Peptonic Medical AB Grants Patent in Europe for Relief of Provoked Vulvodynia in Women, Product Ready for Launch CI
Peptonic Medical AB Announces Organizational Changes CI
Sweden’s Peptonic Medical Names New CFO MT
PEPTONIC medical AB Announces Chief Financial Officer Changes CI
PEPTONIC medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Peptonic Medical Plans SEK61 Million Shares, Warrants Issue MT
Peptonic Medical Secures US Patent for Vaginal Yeast Infections Treatment MT
Sweden’s Peptonic Medical Enters Benelux Distribution Deal for Women's Self-care Products MT
Peptonic Medical AB Strengthens Its Position in Europe Through an Exclusive Distribution Agreement for Vagivital and Vernivia in the Benelux Region CI
Peptonic Medical CFO to Depart in Mid-June MT
PEPTONIC medical AB Announces Resignation of Albert Lindgren as CFO CI
Farmasiet Extends Partnership with Peptonic Medical, Bringing VagVital's Product Portfolio to Norway CI
Peptonic Medical AB Announces Patented Apoteket Offering in 293 Apoteket Stores CI
PEPTONIC medical AB completed the acquisition of Pharmiva AB (OM : PHARM). CI
More news

Analyst Recommendations on PEPTONIC medical AB

Sweden’s Peptonic Medical Enters Benelux Distribution Deal for Women's Self-care Products MT
More recommendations

Press releases PEPTONIC medical AB

Peptonic Medical: Peptonic announces outcome in the rights issue and the directed issue PU
Peptonic announces outcome in the rights issue and the directed issue AQ
Peptonic Medical provides an operational update after the first 120 days with new CEO AQ
Last day of trading with the unit rights in Peptonic AQ
Peptonic Medical AB granted patent in Europe for relief of provoked vulvodynia in women. Product ready for launch. AQ
More press releases

Quotes and Performance

6 months+7.14%
Current year+3.45%
More quotes

Highs and lows

Current year
0.05
Extreme 0.054
0.07
1 year
0.05
Extreme 0.05
0.13
3 years
0.05
Extreme 0.05
1.46
5 years
0.05
Extreme 0.05
4.10
10 years
0.05
Extreme 0.05
19.50
More quotes

Managers and Directors - PEPTONIC medical AB

Managers TitleAgeSince
Erik Sundquist CEO
 Chief Executive Officer 54 21-04-13
Hadar Kessary CTO
 Chief Tech/Sci/R&D Officer - -
Dan Christer Markusson COO
 Chief Operating Officer 64 08-12-31
Members of the board TitleAgeSince
Tarek Shoeb BRD
 Director/Board Member 55 23-05-23
Karl Blom BRD
 Director/Board Member 55 -
Anders Norling BRD
 Director/Board Member 58 22-05-23
More insiders

Company Profile

Peptonic Medical AB is a Sweden-based company active in the field of biotechnology. The Company develops estrogen-free pharmaceuticals for treatment of vaginal atrophy. The Company's main drug candidate is Vagitocin, an oxytocin-based pharmaceutical preparation for the treatment of vaginal atrophy and other menopause-related symptoms. The patented treatment is based on local, vaginal application of oxytocin to rejuvenate the vaginal mucosa. Vagitocin is to enter phase III clinical trials in Europe and the United States.
Sector
Biotechnology & Medical Research
Calendar
2024-08-12 - Q2 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PEPTONIC MEDICAL AB Stock PEPTONIC medical AB
+3.45% 8.76M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.19% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.91% 114B
BIONTECH SE Stock BioNTech SE
-19.80% 20.43B
GENMAB A/S Stock Genmab A/S
-16.19% 16.55B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.45% 16.45B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.35% 15.59B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+66.67% 15.19B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.13% 13.54B
INSMED INCORPORATED Stock Insmed Incorporated
+119.39% 10.96B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PMED Stock